Integrating GLP-1s into the Future of MSK Care

WHITE PAPER | DECEMBER 2023

Obesity and musculoskeletal (MSK) conditions impact a major portion of the American population. With glucagon-like peptide-1 agonists (GLP-1s) rapidly transforming obesity care as well as employer and payer bottom lines, it's more important than ever to consider strategies for sustainable impact. This white paper explores the comorbid nature of obesity and pain and the need for holistic, doctor-led care to navigate the complexities of GLP-1s for long-term gains.

Download this report to learn:

• The high impact of obesity and MSK conditions, along with the web of comorbidities they create
• The staggering total costs of care attributed to these issues
• The pros and cons of using GLP-1s to address obesity and weight-related MSK pain
• The case for implementing GLP-1s within a holistic care model that simultaneously addresses root-cause lifestyle and behavior factors
• Clear steps employers and payers can take to curb high-cost claims and improve long-term outcomes for obesity and MSK pain